Literature DB >> 25250643

Dosage of rituximab in systemic sclerosis: 2-year results of five cases.

F C Moazedi-Fuerst1, S M Kielhauser, K Bodo, W B Graninger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25250643     DOI： 10.1111/ced.12450

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN： 0307-6938            Impact factor:   3.470


× No keyword cloud information.
  3 in total

Review 1.  Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?

Authors:  Antonia Valenzuela; Lorinda Chung
Journal:  J Scleroderma Relat Disord       Date:  2021-10-28

2.  Rituximab in early systemic sclerosis.

Authors:  Maaike Boonstra; Jessica Meijs; Annemarie L Dorjée; Nina Ajmone Marsan; Anne Schouffoer; Maarten K Ninaber; Koen D Quint; Femke Bonte-Mineur; Tom W J Huizinga; Hans U Scherer; Jeska K de Vries-Bouwstra
Journal:  RMD Open       Date:  2017-07-28

3.  Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis.

Authors:  Paul Gressenberger; Philipp Jud; Gabor Kovacs; Sonja Kreuzer; Hans-Peter Brezinsek; Katharina Guetl; Viktoria Muster; Ewald Kolesnik; Albrecht Schmidt; Balazs Odler; Gabriel Adelsmayr; Peter Neumeister; Luka Brcic; Sabine Zenz; Kurt Weber; Thomas Gary; Marianne Brodmann; Winfried B Graninger; Florentine C Moazedi-Fürst
Journal:  J Pers Med       Date:  2021-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.